Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial

Key Points

• Adding tocilizumab improves treatment outcomes in triple-negative breast cancer patients, showing promising efficacy.
• In a controlled environment, 30% of participants experienced significant tumor reduction after the combination therapy.
• This clinical trial examines safety and response rate, utilizing a prospective phase 1/2 design to gather necessary evidence.
• Potential benefits of the combination therapy emphasize the need for further validation in larger patient cohorts.